Overview
Find detailed information on selected clinical trials for Acute Myeloid Leukemia (AML) and Myelodysplasia – Therapy for Relapse and Myelodysplasia at Cincinnati Children's Hospital Medical Center.
There are two versions of some of the trials. While they contain the same basic information, one version is geared toward healthcare professionals and the other is geared toward families.
| Trial | Healthcare Professional Version | Family-Friendly Version |
|---|
| OSU 0479: Flavopiridol in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | Professional | Family-Friendly |
| ADVL0413: Phase I Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children with Refractory Solid Tumors or Refractory Leukemias | Professional | Family-Friendly |
| AAML06P1: Phase I/II Pilot Study of Lestaurtinib, Cytarabine, and Idarubicin in Younger Patients With Relapsed or Refractory FLT3-Mutant Acute Myeloid Leukemia | Professional | |
| AAML0523: Phase I/II Study of Clofarabine and Cytarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | Professional | |
| AAML05P1: A Phase II Pilot Study of Killer Immunoglobulin-Like Receptor-Incompatible Unrelated Donor Hematopoietic Cell Transplantation in Young Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia | Professional | |
| AAML07P1: A Phase II Pilot Study of Bortezomib and Reinduction Chemotherapy in Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia | Professional | |
